Clinical Trial Update: Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease [Phase 2, Phase 3]

View source ↗

Summary

AgeneBio's AGB101 in mild cognitive impairment due to Alzheimer's disease has completed Phase 2/Phase 3 with results posted on 2024-05-17.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease Prodromal
• Cognitive Impairment

Drugs mentioned

• AGB101

Snippet

Sponsor: AgeneBio | Conditions: Mild Cognitive Impairment, Prodromal Alzheimer's Disease | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2024-05-17